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Abstract
Objective: To analyze the prevalence of diagnosed and suspected autoinflammatory diseases in Eastern and
Central European (ECE) countries, with a particular interest on the diagnostic facilities in these countries.
Methods: Two different strategies were used to collect data on patients with periodic fever syndromes from ECE
countries- the Eurofever survey and collection of data with the structured questionnaire.
Results: Data from 35 centers in 14 ECE countries were collected. All together there were 11 patients reported
with genetically confirmed familial Mediterranean fever (FMF), 14 with mevalonate-kinase deficiency (MKD), 11 with
tumor necrosis factor receptor associated periodic syndrome (TRAPS) and 4 with chronic infantile neurological
cutaneous and articular syndrome (CINCA). Significantly higher numbers were reported for suspected cases which
were not genetically tested. All together there were 49 suspected FMF patients reported, 24 MKD, 16 TRAPS,
7 CINCA and 2 suspected Muckle-Wells syndrome (MWS) patients.
Conclusions: The number of genetically confirmed patients with periodic fever syndromes in ECE countries is very
low. In order to identify more patients in the future, it is important to organize educational programs for increasing
the knowledge on these diseases and to establish a network for genetic testing of periodic fever syndromes in ECE
countries.
Introduction
In the last decade the etiologic background of several
monogenic autoinflammatory syndromes has been iden-
tified including FMF, MKD, TRAPS, CAPS - CINCA,
FCAS and MWS, Blau syndrome and PAPA. Specific
mutations of the genes encoding proteins that modulate
inflammasome activity have been discovered for these
syndromes. Periodic fever syndrome in which no muta-
tion has been found so far is PFAPA syndrome [1,2].
The spectrum of autoinflammatory diseases is still
expanding with continuous reports of novel genetic
syndromes [3,4]. With better understanding and genetic
testing the number of patients diagnosed with periodic
fever syndromes is increasing but there are probably
many unrecognized cases especially in countries where
these diseases are rare.
To our knowledge, the frequency of periodic fever
syndromes in Eastern and Central European (ECE)
countries has not been reported so far. In this study we
aimed to identify the prevalence of diagnosed and sus-
pected periodic fever syndromes and other autoinflam-
matory diseases in ECE countries.
2. Methods
We performed a cross-sectional survey on periodic fever
syndromes in ECE countries. Two different strategies
were used to collect data on patients with periodic fever
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questionnaire administered to 54 pediatric rheumatology
centers in ECE countries, members of PRINTO, ii) col-
lection of data with the structured questionnaire distrib-
uted by e-mail to the pediatric immunologists included
in the “Jp r o j e c t ” which is a physicians’ education
campaign promoted by ESID in order to sensitize pedia-
tricians in ECE countries to the recognition of immune-
mediated diseases. Questionnaire was also sent to other
pediatricians with an interest in rheumatology and
immunology, not included in PRINTO or ESID net-
works, mainly working in the tertiary care centers of
pediatric rheumatology and immunology in ECE coun-
tries. Two rounds of e-mails with structured question-
naires were sent for both initiatives.
In total, the questionnaire was sent to 69 physicians
from 16 ECE countries, including Albania, Bulgaria, Bos-
nia and Herzegovina, Croatia, Czech Republic, Estonia,
Hungary, Latvia, Lithuania, Macedonia, Montenegro,
Poland, Romania, Serbia, Slovakia and Slovenia. Accord-
ing to the 2007 Eurostat data for each included country,
it is estimated that 123.6 million people live in these
countries [5].
The structured questionnaire was mainly focused on
monogenic inflammatory diseases. In particular we
asked each center about the number of patients with a
genetically confirmed diagnosis of monogenic autoin-
flammatory disease, where the genetic testing was per-
formed and the possibility of genetic testing within the
country. A suspected case was defined on the basis of
the positivity of diagnostic criteria, whenever available
(such as for FMF [6]) and/or on the intention to test for
a given gene associated with autoinflammatory disease.
We were also interested in the numbers of patients with
suspected syndromes. In its third part the questionnaire
included queries on the number of patients with other
diseases grouped under the term autoinflammatory.
Results
All together we received data from 37 physicians from
35 centers (54% combined response rate for both sur-
veys) from 14 ECE countries including Albania, Bosnia
and Herzegovina, Bulgaria, Croatia, Czech Republic,
Hungary, Latvia, Lithuania, Macedonia, Poland, Roma-
nia, Serbia, Slovakia and Slovenia. The estimated resi-
dent population in these countries is 121.5 million and
the number of children 0-19 years is approximately 27.0
million. This data was obtained from the latest available
statistical report for each participating country.
Among the physicians who responded to the survey
the distribution of specialists was as follows: 14 pediatric
rheumatologists, 8 pediatric immunologists and 11
pediatricians with interest in this field.
Genetically confirmed patients with monogenic
periodic fevers
The overall numbers of patients reported with FMF,
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Table 1. Five adult patients were included- 3 with MKD
and 2 with TRAPS. No country reported more than 2
genetically confirmed FMF patients. The majority of
MKD patients were from the Czech Republic (8). Patients
carrying TNFRSF1A mutations were reported from the
Czech Republic (4), Hungary (3), Poland (2), Latvia (1)
and Slovenia (1). CINCA patients were reported from
Hungary (2), Czech Republic (1) and Slovakia (1).
One genetically confirmed case of Blau syndrome was
reported from Croatia. Genetic testing was done in
Portland, Oregon, USA.
Genetic testing for suspected FMF patients from Slove-
nia was performed at the University Children’s Hospital
Ljubljana and for patients from Macedonia and Serbia at
the Medical faculty Skopje. At the time of our survey, no
genetic testing for other autoinflammatory diseases was
available in ECE countries. Six centers from ECE coun-
tries sent DNA for genetic testing for periodic fever syn-
dromes to Genova (Italy), two centers to Germany,
including one to University of Freiburg, two centers to
Turkey, one center to Montpellier (France), London
(UK), Roma (Italy) and Barcelona (Spain).
Suspected cases of monogenic periodic fever syndromes
and reported cases of other autoinflammatory diseases
The majority of patients with suspected FMF were from
Romania (13), followed by Poland (8), Bulgaria (5), Hun-
gary (4) and Croatia (4). Two adult patients were
included. Other countries reported 3 or less patients
with suspected FMF.
Among suspected MKD patients the highest number
was reported from Romania (5), followed by Serbia (4),
Czech Republic (3) and Slovakia (3).
Table 1 Genetically confirmed and suspected cases of
periodic fever syndromes in ECE countries and estimated
number of patients per number of children 0-19 years
Periodic
fever
syndrome
Genetically
confirmed
cases
Suspected
cases
Total Estimated number
per number of
children 0-19 years*
FMF 11 49 60 1/465.500
MKD 14 24 38 1/771.400
TRAPS 11 16 27 1/1.080.000
CINCA 4 7 11 1/2.454.500
* Adult patients were excluded from calculation.
FMF- familial Mediterranean fever
MKD- mevalonate-kinase deficiency
TRAPS- tumor necrosis factor (TNF) receptor associated periodic syndrome
CINCA- chronic infantile neurological, cutaneous and articular syndrome
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was reported from Poland (6) followed by the Czech
Republic (3). One suspected TRAPS patient was
reported from Albania, Croatia, Hungary, Latvia, Roma-
nia, Serbia and Slovakia.
On the basis of their clinical presentation some
patients were included in the study as suspected CAPS.
Three suspected CINCA cases were referred from
Poland and one from the Czech Republic, Hungary, Lat-
via and Slovakia. Two suspected FCAS patients were
reported from Croatia and one from Serbia. One sus-
pected MWS case was reported from Latvia and Poland.
One suspected PAPA case was reported from the Czech
Republic and one suspected case with Blau syndrome
from Hungary.
The data about other reported autoinflammatory dis-
eases are presented in Table 2. Two adult patients were
included- 1 PFAPA patient and patient with Schnitzler
syndrome.
Discussion
Published studies investigating periodic fever syndromes
were mainly conducted in Mediterranean countries,
western European countries and United States. To our
knowledge, there has been no systematic evaluation of
patients with periodic fevers in ECE countries.
The aim of this study has been to find out if periodic
fever syndromes and other autoinflammatory diseases
are recognized in ECE countries. We contacted all phy-
sicians from eastern and central Europe who are mem-
bers of PRINTO and ESID (J-project for eastern and
central European countries) and pediatricians with an
interest in rheumatology and immunology working in
the tertiary care centers of pediatric rheumatology and
immunology in ECE countries. The response rate for
surveys was 54% which is a possible limitation to the
collected data. We believe that the main reason for this
is linked to the low awareness of these diseases in ECE
countries.
The estimated frequency of FMF patient in ECE coun-
tries appears exceedingly low comparing to the data
from Western European countries and it is likely that
many FMF patients remain unrecognized. It is possible
that clinical presentation of FMF is milder or different
in ECE countries because of environmental modifiers.
The estimated frequency of FMF in Mediterranean
population ranges from 1/256 among North African
Jews to 1/500 among Armenians and Israelis [7]. Lower
but significant frequencies have been reported in other
countries around the Mediterranean Sea [8,9]. In some
patients with clinical features of FMF no mutation of
the MEFV gene could be identified. In the Western Eur-
opean countries, only a minority of patients’ compatible
with FMF present MEFV mutations [8].
Genetically confirmed MKD was in our survey
reported in 14 patients, which is the highest number
among all genetically confirmed periodic fever syn-
dromes in ECE countries. Moreover, an MKD was sus-
pected in further 24 cases. According to these data, it
seems reasonable that MKD may play a relevant role as
a possible cause of inherited periodic fever syndromes in
ECE countries, as already observed in populations other
than Dutch or north-European [10-12].
The number of patients with recurrent fever carrying
one mutation of TNFRSF1A gene in ECE countries was
equal to that observed for genetically confirmed FMF
cases. TRAPS was originally considered an exceedingly
rare disease with only few families described in the lit-
erature. During the past decades more than 50 disease
associated mutations have been identified in hundreds
of patients with different ethnic backgrounds [13]. Since
the survey was not aimed to collect information on the
type of mutations found for each patient we cannot
exclude that part of the mutations found were hypo-
morphic variants of the gene, such as R92Q or P46L.
CINCA is a very rare congenital inflammatory disease
[ 1 4 ]a n dw ew e r ea b l et oi d e n t i f yo n l yf o u rp a t i e n t s
from ECE countries.
In the present study, a relevant number of patients
were classified as PFAPA. It is likely that at least part of
the 282 patients with a PFAPA phenotype identified in
ECE countries might also be positive at genetic testing
[15].
In the majority of patients included in the survey
genetic analysis was not done. With the effort of the
Eurofever project http://www.printo.it/eurofever the net-
work of laboratories that offer genetic testing for peri-
odic fever syndromes was established. The next
important step is to further spread the knowledge about
these rare diseases among physicians of different special-
ties in ECE countries. A low number of trained pediatric
rheumatologists and immunologists in these countries is
likely one of the contributing factors for low recognition
of these diseases. With the purpose to improve the
knowledge about autoinflammatory diseases in the
Table 2 Other reported autoinflammatory diseases
Autoinflammatory disease Reported
cases
PFAPA 282
Behçet disease 26
CRMO 23
Idiopathic recurrent pericarditis 2
Schnitzler syndrome 1
PFAPA- periodic fever syndrome with aphthous stomatitis, pharyngitis and
cervical adenopathy
CRMO- chronic recurrent multifocal osteomyelitis
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educational meeting was organized in October 2009 in
Ljubljana, Slovenia. The meeting was officially supported
by the PReS and the J Project, and was attended by 121
participants from 22 countries.
In summary, this study presents the first data on the
prevalence of diagnosed and suspected autoinflamma-
tory diseases in ECE countries. It demonstrates that all
recognized periodic fever syndromes do affect also
patients from ECE countries, with a frequency which
appears to be lower than in the Mediterranean and
W e s t e r nE u r o p e a nc o u n t r i e s .I no r d e rt oi d e n t i f ym o r e
patients in the future, it is important to continue with
educational activities, that is one of the main aims of
the Eurofever project.
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